Skip to Main Content

Author Details

Jason S Lee
QIMR Berghofer Medical Research Institute
2003
41
23
PMIDPaper TitleJournal TitlePublished Year
36594463IL-10-producing Th1 cells possess a distinct molecular signature in malariaJ Clin Invest2023
37072858COMMD3 loss drives invasive breast cancer growth by modulating copper homeostasis.J Exp Clin Cancer Res2023
36787259IL-10-producing Th1 cells possess a distinct molecular signature in malaria.J Clin Invest2023
36594463IL-10-producing Th1 cells possess a distinct molecular signature in malariaJ Clin Invest2023
37072858COMMD3 loss drives invasive breast cancer growth by modulating copper homeostasis.J Exp Clin Cancer Res2023
36787259IL-10-producing Th1 cells possess a distinct molecular signature in malaria.J Clin Invest2023
35149587Combined Inhibition of G9a and EZH2 Suppresses Tumor Growth via Synergistic Induction of IL24-Mediated Apoptosis.Cancer Res2022
35149587Combined Inhibition of G9a and EZH2 Suppresses Tumor Growth via Synergistic Induction of IL24-Mediated Apoptosis.Cancer Res2022
34316709Genome instability and pressure on non-homologous end joining drives chemotherapy resistance via a DNA repair crisis switch in triple negative breast cancer.NAR Cancer2021
33589432G9a Inhibition Enhances Checkpoint Inhibitor Blockade Response in Melanoma.Clin Cancer Res2021
33669182Histone Modifying Enzymes in Gynaecological Cancers.Cancers (Basel)2021
34316709Genome instability and pressure on non-homologous end joining drives chemotherapy resistance via a DNA repair crisis switch in triple negative breast cancer.NAR Cancer2021
34570837Correction to 'Genome instability and pressure on non-homologous end joining drives chemotherapy resistance via a DNA repair crisis switch in triple negative breast cancer'.NAR Cancer2021
33669182Histone Modifying Enzymes in Gynaecological Cancers.Cancers (Basel)2021
33589432G9a Inhibition Enhances Checkpoint Inhibitor Blockade Response in Melanoma.Clin Cancer Res2021
34570837Correction to 'Genome instability and pressure on non-homologous end joining drives chemotherapy resistance via a DNA repair crisis switch in triple negative breast cancer'.NAR Cancer2021
32292512G9a-mediated repression of CDH10 in hypoxia enhances breast tumour cell motility and associates with poor survival outcome.Theranostics2020
31910858Chromatin interactome mapping at 139 independent breast cancer risk signals.Genome Biol2020
32292512G9a-mediated repression of CDH10 in hypoxia enhances breast tumour cell motility and associates with poor survival outcome.Theranostics2020
32444423ASC Modulates CTL Cytotoxicity and Transplant Outcome Independent of the Inflammasome.Cancer Immunol Res2020
31910858Chromatin interactome mapping at 139 independent breast cancer risk signals.Genome Biol2020
32444423ASC Modulates CTL Cytotoxicity and Transplant Outcome Independent of the Inflammasome.Cancer Immunol Res2020
30121621Molecular basis of distinct oestrogen responses in endometrial and breast cancer.Endocr Relat Cancer2019
30121621Molecular basis of distinct oestrogen responses in endometrial and breast cancer.Endocr Relat Cancer2019
29235923Oncogenic BRAF mutation induces DNA methylation changes in a murine model for human serrated colorectal neoplasia.Epigenetics2018
29626088Granulocytes Are Unresponsive to IL-6 Due to an Absence of gp130.J Immunol2018
29235923Oncogenic BRAF mutation induces DNA methylation changes in a murine model for human serrated colorectal neoplasia.Epigenetics2018
29626088Granulocytes Are Unresponsive to IL-6 Due to an Absence of gp130.J Immunol2018
28630300G9a drives hypoxia-mediated gene repression for breast cancer cell survival and tumorigenesis.Proc Natl Acad Sci U S A2017
28956686G9a in hypoxia: Linking tumor hypoxia and epigenetic regulation.Cell Cycle2017
28759001Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells.Nat Immunol2017
28630300G9a drives hypoxia-mediated gene repression for breast cancer cell survival and tumorigenesis.Proc Natl Acad Sci U S A2017
28738016Eomesodermin promotes the development of type 1 regulatory T (T<sub>R</sub>1) cells.Sci Immunol2017
28197919Sumoylation and Its Contribution to Cancer.Adv Exp Med Biol2017
28197919Sumoylation and Its Contribution to Cancer.Adv Exp Med Biol2017
28956686G9a in hypoxia: Linking tumor hypoxia and epigenetic regulation.Cell Cycle2017
28738016Eomesodermin promotes the development of type 1 regulatory T (T<sub>R</sub>1) cells.Sci Immunol2017
28759001Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells.Nat Immunol2017
26840454Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancer.Oncotarget2016
26890137The anticancer effect of chaetocin is enhanced by inhibition of autophagy.Cell Death Dis2016
26840454Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancer.Oncotarget2016
26928228Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170.Nat Genet2016
27087319Point Mutations in Exon 1B of APC Reveal Gastric Adenocarcinoma and Proximal Polyposis of the Stomach as a Familial Adenomatous Polyposis Variant.Am J Hum Genet2016
27533014Programmed Death-1 Ligand 2-Mediated Regulation of the PD-L1 to PD-1 Axis Is Essential for Establishing CD4(+) T Cell Immunity.Immunity2016
27640304Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation.Am J Hum Genet2016
27640304Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation.Am J Hum Genet2016
27533014Programmed Death-1 Ligand 2-Mediated Regulation of the PD-L1 to PD-1 Axis Is Essential for Establishing CD4(+) T Cell Immunity.Immunity2016
26890137The anticancer effect of chaetocin is enhanced by inhibition of autophagy.Cell Death Dis2016
27087319Point Mutations in Exon 1B of APC Reveal Gastric Adenocarcinoma and Proximal Polyposis of the Stomach as a Familial Adenomatous Polyposis Variant.Am J Hum Genet2016
26928228Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170.Nat Genet2016
  • 1 - 50 of 82

Recommended Authors

Xiongjun Wang
Guangzhou University
Career Start Year 2013
Number of shared co-authors 0
Rahul K Kollipara
McDermott Center for Human Growth and Development.
Career Start Year 2010
Number of shared co-authors 0
Cristina Ivan
The University of Texas MD Anderson Cancer Center
Career Start Year 2010
Number of shared co-authors 2
Wei Zhang
Montefiore Medical Center
Career Start Year 2008
Number of shared co-authors 0
Young K Song
National Cancer Institute, National Institutes of Health
Career Start Year 2007
Number of shared co-authors 6
Henry Yang
Cancer Science Institute of Singapore, National University of Singapore
Career Start Year 2005
Number of shared co-authors 2
David Klinkebiel
University of Nebraska Medical Center
Career Start Year 2005
Number of shared co-authors 0
Anderly C Chueh
Biomedicine Discovery Institute, Monash University
Career Start Year 2005
Number of shared co-authors 1
Hanneke E C Niessen
Maastricht University Medical Center
Career Start Year 2005
Number of shared co-authors 0
Silvano Piazza
International Centre for Genetic Engineering and Biotechnology
Career Start Year 2004
Number of shared co-authors 2
Liuqing Yang
University of Tennessee Health Science Center
Career Start Year 2004
Number of shared co-authors 1
Helai P Mohammad
Collegeville
Career Start Year 2003
Number of shared co-authors 0
Bin Yan
The University of Hong Kong
Career Start Year 2003
Number of shared co-authors 3
Xiaohu Zhang
National Center for Advancing Translational Sciences
Career Start Year 2003
Number of shared co-authors 2
Andrew V Kossenkov
The Wistar Institute
Career Start Year 2003
Number of shared co-authors 4
Michael Slifker
Fox Chase Cancer Center
Career Start Year 2002
Number of shared co-authors 0
Ernesto Guccione
Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
Career Start Year 2001
Number of shared co-authors 1
Sooryanarayana Varambally
University of Alabama at Birmingham, USA O'Neal Comprehensive Cancer Center
Career Start Year 2001
Number of shared co-authors 0
Yonghong Wang
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Career Start Year 2001
Number of shared co-authors 6
Adam J Krieg
Oregon Health and Sciences University
Career Start Year 1999
Number of shared co-authors 3
Joyce E Ohm
Roswell Park Comprehensive Cancer Center
Career Start Year 1999
Number of shared co-authors 0
Jianjun Shen
The University of Texas MD Anderson Cancer Center
Career Start Year 1998
Number of shared co-authors 0
Dongquan Chen
University of Alabama at Birmingham
Career Start Year 1997
Number of shared co-authors 1
Jun Yao
The University of Texas MD Anderson Cancer Center
Career Start Year 1997
Number of shared co-authors 3
Tim H-M Huang
University of Texas Health San Antonio (UTHSA)
Career Start Year 1997
Number of shared co-authors 2
Phillip Buckhaults
University of South Carolina
Career Start Year 1993
Number of shared co-authors 1
Wei Zhang
The University of Texas MD Anderson Cancer Center
Career Start Year 1988
Number of shared co-authors 1
Kristian Helin
The Institute of Cancer Research
Career Start Year 1988
Number of shared co-authors 2
Rakesh Kumar
Rutgers New Jersey Medical School
Career Start Year 1987
Number of shared co-authors 2
Martin J Walsh
Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai
Career Start Year 1987
Number of shared co-authors 2

Collaborators

Nicola Waddell
QIMR Berghofer Medical Research Institute
Co-authored papers 7
Frank Gannon
QIMR Berghofer Medical Research Institute
Co-authored papers 7
Stacey L Edwards
QIMR Berghofer Medical Research Institute
Co-authored papers 6
Juliet D French
QIMR Berghofer Medical Research Institute
Co-authored papers 6
Haran Sivakumaran
QIMR Berghofer Medical Research Institute
Co-authored papers 5
Georgia Chenevix-Trench
QIMR Berghofer Medical Research Institute
Co-authored papers 5
Jonathan Beesley
QIMR Berghofer Medical Research Institute
Co-authored papers 5
Daehee Hwang
Co-authored papers 3
Donal J Brennan
National Centre for Peritoneal Malignancy, Mater Misericordiae University Hospital
Co-authored papers 3
Paul D P Pharoah
Center for Cancer Genetic Epidemiology, University of Cambridge
Co-authored papers 3
Alison M Dunning
Co-authored papers 3
Diether Lambrechts
Co-authored papers 3
Douglas F Easton
University of Cambridge
Co-authored papers 3
Peter A Fasching
Otto-Friedrich-University Bamberg
Co-authored papers 3
Javier Ben??tez
Instituto de Salud Carlos III
Co-authored papers 2
Vessela N Kristensen
Faculty of Clinical Medicine, University of Oslo
Co-authored papers 2
Jonine D Figueroa
The Usher Institute, The University of Edinburgh
Co-authored papers 2
Daniel L Worthley
South Australian Health and Medical Research Institute
Co-authored papers 2
Sander Canisius
The Netherlands Cancer Institute
Co-authored papers 2
Beth Y Karlan
David Geffen School of Medicine, University of California los angeles
Co-authored papers 2
Hoda Anton-Culver
University of California irvine
Co-authored papers 2
Xiao-Ou Shu
Co-authored papers 2
Sunil R Lakhani
University of Queensland
Co-authored papers 2
David E Goldgar
University of Utah
Co-authored papers 2
Jenny Chang-Claude
German Cancer Research Center (DKFZ)
Co-authored papers 2
Christopher A Haiman
University of Southern California
Co-authored papers 2
Xiaoqing Chen
QIMR Berghofer Medical Research Institute
Co-authored papers 2
Peter J Hulick
Neaman Center for Personalized Medicine, NorthShore University HealthSystem
Co-authored papers 2
Noralane M Lindor
Mayo Clinic
Co-authored papers 2
Qiuyin Cai
Co-authored papers 2
Release 1.2